Solid Biosciences Inc. Common Stock (SLDB)

Price$7.14

Value ScoreD

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)14.16%

Price vs S&P 500 (4W)-3.98%

VGM Score43.41

Market Capitalization$702.93M

All Metrics

Book Value / Share (Quarterly)$3.80

P/TBV (Annual)0.27x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-1.76

Price vs S&P 500 (YTD)19.83%

Net Profit Margin (TTM)-588.30%

EPS (TTM)$-1.95

10-Day Avg Trading Volume1.22M

EPS Excl Extra (TTM)$-1.95

EPS (Annual)$-3.05

ROI (Annual)-90.27%

Net Profit Margin (5Y Avg)-2019.34%

Cash / Share (Quarterly)$3.87

ROA (Last FY)-66.26%

EBITD / Share (TTM)$-1.98

ROE (5Y Avg)-61.82%

Operating Margin (TTM)-591.14%

Cash Flow / Share (Annual)$-1.99

P/B Ratio1.88x

P/B Ratio (Quarterly)1.89x

Net Income / Employee (Annual)$-1,033,100

EV / Revenue (TTM)27.44x

Net Interest Coverage (TTM)-65.60x

ROA (TTM)-61.98%

EPS Incl Extra (Annual)$-3.05

Current Ratio (Annual)6.14x

Quick Ratio (Quarterly)12.59x

3-Month Avg Trading Volume1.28M

52-Week Price Return56.62%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$7.20

P/S Ratio (Annual)86.89x

Asset Turnover (Annual)0.03x

52-Week High$8.87

Operating Margin (5Y Avg)-2044.22%

EPS Excl Extra (Annual)$-3.05

CapEx CAGR (5Y)5.08%

Tangible BV CAGR (5Y)26.66%

26-Week Price Return21.96%

Quick Ratio (Annual)5.65x

13-Week Price Return-6.42%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)13.10x

Enterprise Value$405.83M

Asset Turnover (TTM)0.07x

Book Value / Share Growth (5Y)-37.11%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-1062.79%

Cash / Share (Annual)$2.38

3-Month Return Std Dev74.33%

Net Income / Employee (TTM)$-1,585,000

ROE (Last FY)-91.08%

Net Interest Coverage (Annual)-81.57x

EPS Basic Excl Extra (Annual)$-3.05

Receivables Turnover (TTM)162.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.95

Receivables Turnover (Annual)147.16x

ROI (TTM)-74.36%

P/S Ratio (TTM)47.53x

Pretax Margin (5Y Avg)-2019.34%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$10.82

Price vs S&P 500 (52W)33.93%

Year-to-Date Return28.01%

5-Day Price Return7.76%

EPS Normalized (Annual)$-3.05

ROA (5Y Avg)-48.03%

Net Profit Margin (Annual)-1062.79%

Month-to-Date Return-1.63%

Cash Flow / Share (TTM)$-4.97

EBITD / Share (Annual)$-3.11

Operating Margin (Annual)-1090.48%

LT Debt / Equity (Annual)0.80x

ROI (5Y Avg)-61.28%

LT Debt / Equity (Quarterly)0.94x

EPS Basic Excl Extra (TTM)$-1.95

P/TBV (Quarterly)0.39x

P/B Ratio (Annual)2.44x

Pretax Margin (TTM)-588.30%

Book Value / Share (Annual)$2.28

Price vs S&P 500 (13W)-15.50%

Beta2.44x

Revenue / Share (TTM)$0.00

ROE (TTM)-74.45%

52-Week Low$3.79

vGradeD

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.52est. -0.44

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.32

4.35

Industry Peers — Biological Products(179)

Symbol	Value Score	Growth Score	Momentum Score	Price
SLDBSolid Biosciences Inc. Common Stock	D	—	C	$7.14
AMGNAmgen Inc	C	C	C	$355.20
GILDGilead Sciences Inc	C	B	C	$125.59
ARGXargenx SE American Depositary Shares	D	A	B	$893.52
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$153.87
BIIBBiogen Inc. Common Stock	B	D	B	$200.05
BNTXBioNTech SE American Depositary Share	C	C	C	$90.54
MRNAModerna, Inc. Common Stock	C	B	B	$49.91
NBIXNeurocrine Biosciences Inc	C	B	B	$159.76
EXELExelixis Inc	C	B	B	$53.13
KRYSKrystal Biotech, Inc. Common Stock	D	B	A	$317.97

About

Solid Biosciences is a gene therapy company developing treatments for neuromuscular and cardiac diseases, with a primary focus on Duchenne muscular dystrophy (DMD). The company's pipeline includes SB-001 and other programs spanning corrective therapies, disease-modifying therapies, and assistive devices for genetic muscle-wasting conditions.